Financial Industry Veteran Mary Hentges Joins Akili’s Board of Directors
27 October 2022 - 10:00PM
Business Wire
Former chief financial officer at PayPal and
CBS Interactive brings leadership experience spanning financial
services, technology and healthcare industries
Akili, Inc. (NASDAQ: AKLI), a leading digital medicine company,
today announced the appointment of Mary Hentges to the company’s
board of directors, effective October 25, 2022. Hentges will serve
as chair of the Audit Committee and a member of the Compensation
Committee. Mary has extensive executive-level and financial
experience with both public and private companies. Hentges’ proven
track record serving as chief financial officer at several
high-growth companies will support Akili as it enters its next
phase of growth with the commercialization of its flagship product,
EndeavorRx.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221027005129/en/
(Photo: Business Wire)
“We are honored and excited to have Mary join our board of
directors,” said Eddie Martucci, co-founder and Chief Executive
Officer of Akili. “Her experience scaling high-growth,
industry-defining businesses, and her passion for bold missions
that have the potential to change society, will be invaluable as we
work to establish the first prescription digital therapeutic in
routine clinical care.”
Hentges has held the roles of interim CFO at ShotSpotter, Inc.,
a precision-policing solutions company; CFO of YapStone, Inc., a
digital payments provider; CFO of CBS Interactive, an internet
media company; and CFO of PayPal, Inc., a global digital financial
services provider. Prior to those positions, Hentges worked in a
variety of roles in finance at Agilent Technologies, Inc., and
Hewlett-Packard, Inc., diversified technology companies.
Additionally, Hentges holds several board positions, including
director and audit committee member, Upstart Holdings, Inc;
director and finance committee chair, nominating and governance
committee member and executive committee member, Kaiser Permanente
Bernard J. Tyson School of Medicine; and director and investment
committee member, ASU Foundation.
“I look forward to supporting Akili and its mission of igniting
new hope for the millions of people living with cognitive health
issues,” said Hentges. “Akili is inspirational in its effort to
create a new class of digital medicines delivered through
captivating video game experiences. The potential of providing some
relief from cognitive issues while avoiding the potential side
effects of compound-based medicines is a game changer for patients,
parents, and physicians.”
Hentges joins the company’s current board members William (BJ)
Jones, chief commercial officer of Biohaven Pharmaceuticals;
Christine Lemke, co-chief executive officer and a director of
Evidation Health; Ken Ehlert, former chief scientific officer at
UnitedHealth Group; Adam Gazzaley, M.D., Ph.D., co-founder of Akili
and founding director of Neuroscape at UCSF; Eddie Martucci, Ph.D.,
co-founder and CEO of Akili; and Chamath Palihapitiya, founder and
CEO of Social Capital and chairman and managing partner of Social
Capital Suvretta Holdings, who serves as chair of the company’s
board.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Akili’s approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device, but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. These forward-looking statements generally are
identified by the words “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks and uncertainties related to the development and
commercialization of EndeavorRx and other digital medicine and
other risks identified in our filings made with the Securities and
Exchange Commission (SEC). We caution you not to place undue
reliance on any forward-looking statements, which speak only as of
the date hereof and should not be relied upon as representing the
company’s views as of any subsequent date. We disclaim any
obligation to publicly update or revise any such statements to
reflect any change in expectations or in events, conditions or
circumstances on which any such statements may be based, or that
may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221027005129/en/
Media: Julie DiCarlo SVP, Communications
julie@akiliinteractive.com
Akili (NASDAQ:AKLI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akili (NASDAQ:AKLI)
Historical Stock Chart
From Apr 2023 to Apr 2024